New Phase 2a data show the oral IPF therapy GRI-0621 modulates immune cell activity in adults with idiopathic pulmonary ...

Cumulus Neuroscience, a leading innovator in brain health technology for clinical trials, today announced the publication of ...

BrainsWay’s strategic investment in Neurolief paved the way for the first and only FDA approved at-home neuromodulation ...

Bicara Therapeutics (NASDAQ:BCAX) used its presentation at the 44th Annual J.P. Morgan Healthcare Conference to outline its ...

Data provide first human validation of cardiac energetics modulation as a therapeutic target in cardiometabolic heart disease, including heart failure with preserved ejection fraction (HFpEF) ...

And the reason for this is because there is so much at stake.” Cars and planes need to be extremely reliable because people ...

Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced the presentation of new ...

The 2025 tsunami is shattering old models, thanks to observations from space. On July 29, 2025, the world’s sixth biggest ...

As we enter 2026, there are two distinct technologies used by clinicians to interact with the brain: Brain-Computer ...

Dewpoint Therapeutics, a US biotech developing condensate-modulating therapeutics, has announced the selection of a ...

At TOXINS 2026, we will demonstrate our continued leadership in neuromodulation through updates on our leading portfolio, and an educational session on Relfydess, an innovative, science-backed ...

BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive brain stimulation technologies ...